On August 8, 2022 POINT Biopharma Global Inc. (NASDAQ: PNT) (the "Company" or "POINT"), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, reported that next week, on Thursday, August 18, 2022 at 12:00 PM ET, the Company will be presenting a 45-minute educational webinar entitled "Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm" (Press release, Point Biopharma, AUG 8, 2022, View Source [SID1234618490]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Topics to be presented at the webinar include:
• Overview of SPLASH trial design (including lead-in phase) and rationale for hormone switches
• What is a control arm benchmark, why PROfound1 & IMbassador2502 were selected as SPLASH benchmarks
• Review current treatment patterns, including sequencing considerations, in real-world clinical settings for mCRPC patients
The webinar will feature presentations from two Thought Leaders: Dr. Oliver Sartor & Dr. Kim Chi. They will be joined by members of the Company’s executive leadership team including Dr. Neil Fleshner, Chief Medical Officer, and Dr. Sherin Al-Safadi, VP Medical Affairs.